GNPX News and Press, Genprex Inc. From 09/11/19

A direct target of miR-138, TUSC2 mimics miR-138 knockdown Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex&#x...

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Offer Hope for Cancer Patients.” To hear the NetworkNewsWire Audio versi...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which de...

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced that it will present at the H.C. Wainwright 21 st Annual Global Investment Conference on September 10, 2019 in New York City. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, wil...

NetworkNewsWire Editorial Coverage : Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer. Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is focused on using gene therapy to tackle lung cancer, developing new drugs that...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market. These ...

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector” and produ...

NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NetworkWire --  Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full pub...

NetworkNewsWire Editorial Coverage : Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) ( GNPX Profi...